Following drugs act against HIV-2 Except:
Core Concept: The main point here is the difference in drug susceptibility between HIV-1 and HIV-2. HIV-2 is less common and some drugs are less effective against it. The core concept is about the mechanism of action of various antiretroviral drugs and their efficacy against different HIV types.
Why the Correct Answer is Right: The correct answer would be a drug that's less effective or not effective against HIV-2. For example, some nucleoside analogs like zidovudine (AZT) might still work, but others like efavirenz (a non-nucleoside reverse transcriptase inhibitor) might have different efficacy. However, more commonly, drugs like protease inhibitors or integrase inhibitors are effective against both, but certain NRTIs or NNRTIs may not. Need to verify which specific drugs are excluded for HIV-2.
Why Each Wrong Option is Incorrect: Let's say the options include drugs like tenofovir, emtricitabine, efavirenz, and a drug like etravirine. Tenofovir and emtricitabine are NRTIs effective against both. Efavirenz is an NNRTI more effective against HIV-1. Etravirine is another NNRTI that's less effective against HIV-2. So if the correct answer is etravirine, then the others are effective.
Clinical Pearl: Remember that HIV-2 treatment is less studied, and some drugs like NNRTIs are not recommended. Protease inhibitors and NRTIs are preferred. Also, resistance patterns differ between HIV-1 and HIV-2.
Need to make sure the correct answer is the one that's ineffective against HIV-2. Let me check specific drugs. Efavirenz is less effective against HIV-2. So if the correct answer is efavirenz, then the explanation would be that it's ineffective against HIV-2. But other NNRTIs like nevirapine might also have issues. Alternatively, maybe the question is about drugs not recommended, like some entry inhibitors. But I need to confirm the exact drugs. Let me recall: The standard of care for HIV-2 includes NRTIs and protease inhibitors. NNRTIs are not as effective. So the correct answer would be an NNRTI like efavirenz. So the answer is the NNRTI option.
**Core Concept**
HIV-1 and HIV-2 differ in drug susceptibility due to distinct viral structure and replication dynamics. Most antiretroviral drugs target conserved enzymes (e.g., reverse transcriptase, protease), but some agents show reduced efficacy against HIV-2, particularly non-nucleoside reverse transcriptase inhibitors (NNRTIs).
**Why the Correct Answer is Right**
The correct answer is **efavirenz** (a classic NNRTI). HIV-2 reverse transcriptase has structural differences from HIV-1, rendering NNRTIs ineffective. Efavirenz binds to a specific pocket in HIV-1 reverse transcriptase absent in HIV-2, making it a poor choice for monotherapy in